News

Pharming gets cash injection
Enlarge image

BusinessNetherlands

Pharming gets cash injection

02.08.2012 - Dutch Pharming Group NV has baged an equity working capital facility of up to €10m to push Ruconest (conestat alfa) to the US market.

The Leiden-based company secured a financing of up to €10m led by Kingsbrook Opportunities Master Fund LP. Ruconest, a recombinant C1 inhibitor to treat angioedema attacks in patients with the congenital disorder HEA. The drug is produced through the company's proprietary technology in milk of transgenic rabbits. The working capital facility should enable Pharming's cash runway to reach the anticipated read out of Study 1310 for Ruconest in the US and the associated US$10m milestone payment and a further US$5m upon acceptance of the BLA by the FDA from US partner, Santarus, Inc.

Pharming will have the option to draw from the working capital facility in tranches in exchange for ordinary shares in the capital. Pharming will retain control of the timing and amount of any funds draw down. Pharming must give notice to the Investors. The investors have the option to purchase up to 600% of the Draw Down Amount.

On signing, Kingsbrook and other investors will receive warrants to purchase up to an aggregate of 16,500,000 ordinary shares in the capital of Pharming. When draw downs have exceeded a total of €2,5m and for every subsequent €2,5m drawn, the Investors will receive additional warrants to purchase up to an additional 16,5 million ordinary shares. The warrants have an exercise period of five years and are exercisable at a strike price equal to 110% of the average of the volume weighted average price of the ordinary shares on the market for the 10 trading days prior to the signing of this agreement. Sijmen de Vries, CEO, said "Pharming is very pleased to have secured this facility against a backdrop of extremely difficult conditions in the capital markets.“ Currently Ruconest is in Phase III testing under a Special Protocol Assessment (SPA) that is intended to support the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). The study with the orphan drug, which is expressed in transgenic rabbits, is expected to be completed by autum this year.

http://www.european-biotechnology-news.com/news/news/2012-03/pharming-gets-cash-injection.html

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

BusinessBelgiumSpain

31.07.2015 Spanish business developer Genetrix has sold its clinical stage cell therapy development subsidiary Coretherapix to Belgian TiGenix in a deal worth up to €267m.

BusinessUKSwitzerland

29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • ERYTECH PHARMA (F)39.50 EUR9.45%
  • PAION (D)2.69 EUR8.47%

FLOP

  • BAVARIAN NORDIC (D)40.26 EUR-10.69%
  • ZELTIA (E)3.69 EUR-8.44%
  • TIGENIX (B)0.73 EUR-7.59%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • DBV TECHNOLOGIES (F)81.03 EUR53.6%
  • IXICO (UK)34.00 GBP41.7%

FLOP

  • BIOTEST (D)27.24 EUR-60.8%
  • BIOTECH PHARMACON (N)9.43 NOK-46.1%
  • TRANSGENE (F)2.80 EUR-23.9%

TOP

  • ADOCIA (F)88.74 EUR587.4%
  • DBV TECHNOLOGIES (F)81.03 EUR328.7%
  • FORMYCON (D)28.70 EUR315.9%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.70 SEK-71.6%
  • NEOVACS (F)1.01 EUR-69.5%

No liability assumed, Date: 03.08.2015